Condition: Corneal Ulcer · Sponsor: University of Illinois at Chicago
The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of allogeneic bone marrow-derived MSCs in patients with nonhealing epitheliopathy (IRB Protocol 2020-0334). In the present study, we want to study the efficacy of this treatment on chronic epitheliopathies.
This description comes directly from the study's public registry record.
Ali R Djalilian, MD · 312-996-8937 · adjalili@uic.edu
Charlotte E Joslin, OD, PhD · 312-996-5410 · charjosl@uic.edu
Always discuss trial participation with your own doctor first.
| Department of Ophthalmology and Visual Sciences | Chicago, Illinois, United States | Recruiting |
| University of Maryland at Baltimore | Baltimore, Maryland, United States | Recruiting |
| Mass Eye and Ear Infirmary | Boston, Massachusetts, United States | Active Not Recruiting |
| University of Pennsylvania, Scheie Eye Institute | Philadelphia, Pennsylvania, United States | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05705024